Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Forever Labs to Utilize Data Collection Platform DataBiologics

09/14/2021 | 09:28am EDT

ANN ARBOR, Mich., Sept. 14, 2021 (GLOBE NEWSWIRE) --  Forever Labs, the parent company of SuperShot® PRP, will utilize DataBiologics to track outcomes for their innovative PRP process that allows autologous extracellular vesicles to be isolated.

Physicians who already collect, review and analyze data related to their orthobiologic treatment outcomes via the DataBiologics platform, can now include SuperShot® PRP procedures in their data. This newly collected data can then be compared to outcomes for standard PRP procedures. 

By using DataBiologics, Forever Labs is ensuring that the safety and efficacy of SuperShot® PRP are tracked and monitored, a top priority for the Forever Labs team.     

"We developed SuperShot® PRP to give clinicians the ability to add autologous extracellular vesicles to their PRP therapies. 

We are excited to be using DataBiologics to track results.  Like them, we believe the best way to forward medicine is to measure and track outcomes with high fidelity."

- Steven Clausnitzer,
  CEO Forever Labs


Forever Labs is passionate about providing autologous, science-based solutions to improve life quality, along with the most cutting-edge solutions for our partner physicians. SuperShot® PRP is founded on this principle. This innovative PRP process is based on a two-phase aqueous system which allows for the concentration of autologous extracellular vesicles (EVs) from the PPP portion of a PRP procedure in a quick, one-minute spin at benchtop centrifuge speeds.  The isolated EVs can then be added back to the PRP fraction for the most complete PRP on the market.  

"At DataBiologics we believe that there is nothing more important than studying the safety and efficacy of orthobiologic treatments. We are extremely pleased to add the SuperShot® PRP device to the DataBiologics platform. Our goal has always been to offer an easy-to-use patient-reported outcomes platform to the orthobiologics industry. Coupled with the excellent product and device breadth within the platform, we will now be able to offer data tracking on SuperShot® PRP to all participating providers utilizing our platform."

- Nancy Ho,
  Executive Director


DataBiologics offers doctors a robust patient-reported outcomes collection platform to study the safety and efficacy of orthobiologic treatments. The simple, user-friendly, and practical application helps assist doctors in collecting real-world, patient data to allow for more informed treatment decisions and better patient care.

Contact Information: 
Forever Labs • Daniele Hughes
888.344.8463 • info@foreverlabs.com

Related Images

Image 1: Forever Labs - SuperShot PRP

This content was issued through the press release distribution service at Newswire.com.


Primary Logo

Forever Labs - SuperShot PRP

Forever Labs - SuperShot PRP

ę GlobeNewswire 2021
Latest news "Companies"
05:03pREGIS CORP : Change in Directors or Principal Officers (form 8-K)
05:03pSENSIENT TECHNOLOGIES CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
05:03pSTARLIGHT U.S. MULTI-FAMILY (NO. 2) CORE PLUS FUND : Announces October 2021 Distributions
05:03pB2DIGITAL, INC. : Entry into a Material Definitive Agreement (form 8-K)
05:02pECORODOVIAS INFRAESTRUTURA E LOGÍSTICA S A : Notice to the Market - Nicolò Caffo Resignation
05:02pCASCADIA ACQUISITION : Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing October 18, 2021 - Form 8-K
05:02pHoeven Announces $5 Million DOE Grant to UND's EERC for PCOR Partnership
05:02pBENTON RESOURCES : and Sokoman Enter into Mutual Participation Agreements Governing Cost Reimbursement Under Their Strategic Exploration AllianceEdit Subject
05:02pMILLICOM INTERNATIONAL CELLULAR S A : Repurchase of shares in Millicom
Latest news "Companies"